On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.
from
https://healthnews010.wordpress.com/2019/04/08/celltrion-and-iprogen-biotech-announce-partnership-for-development-of-novel-adcs/
from https://karlfletcher.blogspot.com/2019/04/celltrion-and-iprogen-biotech-announce.html
from
https://karlfletcher1.tumblr.com/post/184033401013
from https://davidrawlins1.blogspot.com/2019/04/celltrion-and-iprogen-biotech-announce.html
from
https://davidrawlins1.tumblr.com/post/184033493661
from http://bit.ly/2UJuMS0
from
https://jamesprice01.tumblr.com/post/184033566524
No comments:
Post a Comment